BRPI0818201A2 - Composto de azolcarboxamida ou sal do mesmo - Google Patents

Composto de azolcarboxamida ou sal do mesmo

Info

Publication number
BRPI0818201A2
BRPI0818201A2 BRPI0818201A BRPI0818201A2 BR PI0818201 A2 BRPI0818201 A2 BR PI0818201A2 BR PI0818201 A BRPI0818201 A BR PI0818201A BR PI0818201 A2 BRPI0818201 A2 BR PI0818201A2
Authority
BR
Brazil
Prior art keywords
azolcarboxamide
salt composite
composite
salt
Prior art date
Application number
Other languages
English (en)
Inventor
Keizo Sugasawa
Kenichi Kawaguchi
Takaho Nomura
Shunichiro Matsumoto
Takashi Shin
Hidenori Azami
Tomoaki Abe
Akira Suga
Ryushi Seo
Masayuki Tanahashi
Toru Watanabe
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI0818201A2 publication Critical patent/BRPI0818201A2/pt
Publication of BRPI0818201B1 publication Critical patent/BRPI0818201B1/pt
Publication of BRPI0818201B8 publication Critical patent/BRPI0818201B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
BRPI0818201A 2007-10-24 2008-10-23 composto de azolcarboxamida ou sal do mesmo e uso do mesmo para o tratamento de frequência urinária, urgência urinária, incontinência urinária e dores do trato urinário inferior associadas com várias doenças do trato urinário inferior, e várias doenças acompanhadas de dor BRPI0818201B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007276894 2007-10-24
PCT/JP2008/069263 WO2009054468A1 (ja) 2007-10-24 2008-10-23 アゾールカルボキサミド化合物又はその塩

Publications (3)

Publication Number Publication Date
BRPI0818201A2 true BRPI0818201A2 (pt) 2015-04-22
BRPI0818201B1 BRPI0818201B1 (pt) 2019-01-29
BRPI0818201B8 BRPI0818201B8 (pt) 2021-05-25

Family

ID=40579570

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818201A BRPI0818201B8 (pt) 2007-10-24 2008-10-23 composto de azolcarboxamida ou sal do mesmo e uso do mesmo para o tratamento de frequência urinária, urgência urinária, incontinência urinária e dores do trato urinário inferior associadas com várias doenças do trato urinário inferior, e várias doenças acompanhadas de dor

Country Status (21)

Country Link
US (1) US8304547B2 (pt)
EP (1) EP2206707B1 (pt)
JP (1) JP5321467B2 (pt)
KR (1) KR101504787B1 (pt)
CN (1) CN101835764B (pt)
AU (1) AU2008314922B2 (pt)
BR (1) BRPI0818201B8 (pt)
CA (1) CA2703106C (pt)
CY (1) CY1115547T1 (pt)
DK (1) DK2206707T3 (pt)
ES (1) ES2498065T3 (pt)
HR (1) HRP20140970T1 (pt)
IL (1) IL205071A (pt)
MX (1) MX2010004499A (pt)
PL (1) PL2206707T3 (pt)
PT (1) PT2206707E (pt)
RU (1) RU2461551C2 (pt)
SI (1) SI2206707T1 (pt)
TW (1) TWI418557B (pt)
WO (1) WO2009054468A1 (pt)
ZA (1) ZA201002608B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2489040T3 (es) 2008-12-03 2014-09-01 The Scripps Research Institute Cultivos de células madre
RU2595720C2 (ru) 2009-04-09 2016-08-27 Когнишн Терапьютикс, Инк. Ингибиторы снижения когнитивных способностей
US9192585B2 (en) 2009-07-31 2015-11-24 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2011026241A1 (en) * 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
ES2557316T3 (es) * 2009-09-08 2016-01-25 F. Hoffmann-La Roche Ag Compuestos de piridín-3-il-carboxamida 4-sustituidos y métodos de utilización
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
EA201290957A1 (ru) 2010-04-07 2013-04-30 Ф.Хоффманн-Ля Рош Аг Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
WO2012059442A2 (en) * 2010-11-01 2012-05-10 Neurotune Ag Neurotrypsin inhibitors
US20140113898A1 (en) * 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
RU2013140467A (ru) 2011-02-02 2015-03-10 Когнишн Терапьютикс, Инк. Выделенные соединения из масла куркумы и способы применения
AU2012220572A1 (en) * 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
JP5376095B2 (ja) 2011-08-11 2013-12-25 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
CA2845191A1 (en) 2011-09-27 2013-04-04 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2013102826A1 (en) * 2012-01-04 2013-07-11 Pfizer Limited N-aminosulfonyl benzamides
US9242977B2 (en) 2012-04-26 2016-01-26 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
EP3181564B1 (en) 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
WO2014134306A1 (en) 2013-03-01 2014-09-04 Zalicus Pharmaceuticals, Ltd. Heterocyclic inhibitors of the sodium channel
GB201313664D0 (en) * 2013-07-31 2013-09-11 Univ Cardiff Bcl-3 inhibitors
EP3097095A1 (en) * 2014-01-24 2016-11-30 AbbVie Inc. Furo-3-carboxamide derivatives and methods of use
AU2015210852B2 (en) 2014-01-31 2019-01-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN106414438B (zh) * 2014-06-06 2019-12-31 安斯泰来制药株式会社 2-酰氨基噻唑衍生物或其盐
TR201908031T4 (tr) * 2014-08-26 2019-06-21 Astellas Pharma Inc İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu.
CN107690429B (zh) * 2015-04-07 2022-02-25 Ela制药有限公司 用于治疗和/或预防细胞或组织坏死的组合物，其特异性靶向组织蛋白酶c和/或cela1和/或cela3a和/或与其结构相关的酶
PT3286181T (pt) 2015-04-22 2021-04-05 Rigel Pharmaceuticals Inc Compostos de pirazol e método para preparar e usar os compostos
CN105601585B (zh) * 2015-12-17 2018-01-05 浙江工业大学 一种含噻唑环的羧酰胺类化合物及其制备与应用
ES2854750T3 (es) 2016-01-01 2021-09-22 Adama Agan Ltd Proceso para preparar 1,1,3-trioxo-1,2-benzotiazol-6-carboxamida
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102325422B1 (ko) * 2018-05-09 2021-11-11 주식회사 엘지화학 엔테로펩티다아제 억제 활성을 나타내는 신규 화합물
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
PH12022550466A1 (en) 2019-08-30 2023-03-06 Rigel Pharmaceuticals Inc Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
WO2022187303A1 (en) 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
TWI822140B (zh) * 2021-06-24 2023-11-11 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎吡啶衍生物化合物
EP4159743A1 (en) * 2021-09-30 2023-04-05 ETH Zurich Methods for preparing pyridazine compounds
US12384775B2 (en) 2022-03-23 2025-08-12 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors
AR129846A1 (es) * 2022-07-07 2024-10-02 Libra Therapeutics Inc Agonistas de trpml1 con oxazol y usos de estos
TW202535364A (zh) * 2024-01-08 2025-09-16 美商利布拉醫療公司 噻唑trpml1促效劑及其用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395932A (en) 1993-04-30 1995-03-07 G. D. Searle & Co. 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
GB9424379D0 (en) * 1994-12-02 1995-01-18 Agrevo Uk Ltd Fungicides
AU8270898A (en) 1997-06-26 1999-01-19 Eli Lilly And Company Antithrombotic agents
DE69926148D1 (en) 1998-11-09 2005-08-18 Black James Foundation Gastrin und cholecystokinin rezeptor ligande
NZ513639A (en) * 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
JP2001278872A (ja) 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd 新規アミノチアゾール誘導体
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
US6964977B2 (en) 2000-09-01 2005-11-15 Smithkline Beecham Corporation Oxindole derivatives
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
ATE342266T1 (de) 2000-11-16 2006-11-15 Sankyo Co 1-methylcarbapenemderivate
AU2002248432A1 (en) 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
ES2275021T3 (es) 2001-09-27 2007-06-01 Smithkline Beecham Corporation Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico.
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
WO2004071440A2 (en) 2003-02-06 2004-08-26 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
AU2004212490B2 (en) 2003-02-10 2008-05-15 Amgen Inc. Vanilloid receptor ligands and their use in treatments
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
WO2004096795A2 (en) 2003-04-25 2004-11-11 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US7427683B2 (en) 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
CA2539117A1 (en) 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
RU2006120549A (ru) 2003-11-14 2007-12-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20050282840A1 (en) 2004-02-11 2005-12-22 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
JP2007533717A (ja) 2004-04-21 2007-11-22 アストラゼネカ アクチボラグ 化合物
RU2007109073A (ru) 2004-08-13 2008-09-20 Дженентек, Инк. (Us) Ингибиторы для атф-зависимого фермента на основе тиазола
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1637529A1 (en) 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
CA2583392A1 (en) 2004-10-15 2006-04-27 Amgen Inc. Imidazole derivatives as vanilloid receptor ligands
US7705042B2 (en) 2004-10-22 2010-04-27 Janssen Pharmaceutica Nv Class of arylamide compounds useful as inhibitors of c-fms kinase
AR056319A1 (es) 2005-04-22 2007-10-03 Kalypsys Inc Inhibidores de orto-terfinilo de p38 quinasa, composicion farmaceutica y compuestos intermedios
SG159561A1 (en) 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
JP2008543965A (ja) 2005-06-28 2008-12-04 タケダ・ケンブリッジ・リミテッド 複素環式非ペプチドｇｎｒｈ拮抗薬
US7700552B2 (en) 2005-07-29 2010-04-20 Medivir Ab Macrocyclic inhibitors of hepatitis C virus
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
NZ566036A (en) 2005-09-13 2010-06-25 Janssen Pharmaceutica Nv 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor
BRPI0615930A2 (pt) 2005-09-15 2016-08-23 Painceptor Pharma Corp métodos de modular a interação de uma neurotrofina e um receptor de neurotrofina, de tratar dor em um indivíduo, de tratar distúrbio inflamatório em um indivíduo, de tratar um distúrbio neurológico em um indivíduo, e de tratar uma doença ou distúrbio associado aos sistemas geniturinário e/ou gastrointestinal de um indivíduo, e, composto
CA2622960A1 (en) * 2005-09-20 2007-03-29 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
EP2612854B1 (en) 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5076091B2 (ja) 2005-11-28 2012-11-21 マドリガル・ファーマシューティカルズ・インコーポレーテッド ジアシルグリセロールアシルトランスフェラーゼ（ｄｇａｔ）のインヒビター
JP2009529059A (ja) 2006-03-08 2009-08-13 アキリオン ファーマシューティカルズ，インコーポレーテッド 抗ｃ型肝炎ウイルス活性を有する置換アミノチアゾール誘導体
WO2007104557A2 (en) * 2006-03-15 2007-09-20 4Sc Ag Novel heterocyclic nf-kb inhibitors
WO2007123269A1 (ja) 2006-04-19 2007-11-01 Astellas Pharma Inc. アゾールカルボキサミド誘導体
JP5363315B2 (ja) 2006-06-06 2013-12-11 コーナーストーン セラピューティクス インコーポレイテッド 新規ピペラジン、医薬組成物、およびその使用方法
GB0614070D0 (en) 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
EP1881001A1 (en) * 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
MX2009004786A (es) 2006-10-31 2009-06-05 Schering Corp Derivados de anilinopiperazina y sus metodos de uso.
JP5103604B2 (ja) 2006-10-31 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド
AR063531A1 (es) 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
WO2008059214A1 (en) 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors

Also Published As

Publication number Publication date
BRPI0818201B8 (pt) 2021-05-25
ZA201002608B (en) 2011-07-27
TW200932743A (en) 2009-08-01
KR20100071047A (ko) 2010-06-28
EP2206707A1 (en) 2010-07-14
PL2206707T3 (pl) 2015-01-30
IL205071A (en) 2015-08-31
CA2703106A1 (en) 2009-04-30
CN101835764B (zh) 2012-09-19
ES2498065T3 (es) 2014-09-24
EP2206707A4 (en) 2011-08-17
AU2008314922B2 (en) 2013-08-29
RU2461551C2 (ru) 2012-09-20
DK2206707T3 (da) 2014-08-11
EP2206707B1 (en) 2014-07-23
CN101835764A (zh) 2010-09-15
IL205071A0 (en) 2010-11-30
US8304547B2 (en) 2012-11-06
AU2008314922A1 (en) 2009-04-30
JPWO2009054468A1 (ja) 2011-03-10
PT2206707E (pt) 2014-09-25
HRP20140970T1 (hr) 2015-01-30
KR101504787B1 (ko) 2015-03-20
CA2703106C (en) 2015-12-01
JP5321467B2 (ja) 2013-10-23
MX2010004499A (es) 2010-05-20
CY1115547T1 (el) 2017-01-04
RU2010120676A (ru) 2011-11-27
TWI418557B (zh) 2013-12-11
US20100249088A1 (en) 2010-09-30
WO2009054468A1 (ja) 2009-04-30
SI2206707T1 (sl) 2014-11-28
BRPI0818201B1 (pt) 2019-01-29

Similar Documents

Publication Publication Date Title
BRPI0815588A2 (pt) Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
DE602008000880D1 (de) Lenksystem
DE602008002674D1 (de) Lenksystem
BRPI0818380A2 (pt) Combinação de herbicida-protetor
BRPI0816278A2 (pt) forma sal
DE602008004938D1 (de) Fahrzeugaußengriffsystem
EP1998904A4 (en) COMPOSITE SCREEN
BRPI0807004A2 (pt) Sal
DE602007012976D1 (de) Lenksystem
BRPI0920648A2 (pt) Combinações pesticidas contendo sulfoxaflor
BRPI0908880A2 (pt) sistemas de varredoura
DE602008001653D1 (de) Lenksystem
EP2004372A4 (en) Composite mandrel
BRPI0811775A2 (pt) Compostos de policarbonato -e /ou poliuretano-poliorganossiloxano
EP2242680A4 (en) DRIVE SYSTEM
BRPI0920361A2 (pt) materiais de compósito melhorados
BRPI0812359A2 (pt) Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo
DE602008005054D1 (de) Ultraschallsystem
BRPI0820446A2 (pt) Recipente compósito
DE602008004179D1 (de) Motorsteuerungssystem
BRPI0808109A2 (pt) Unidade de bagagem
EP2227553A4 (en) Lac expression system
BRPI0810566A2 (pt) métodos de ativação de transponder
BRPI0818631A2 (pt) Cobertura de carril
EP2214719A4 (en) Metallofullerene-DYE

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2797 DE 13-08-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.